Login
Toggle navigation
Videos
Categories
Trending
Flash is missing. Download it from
Adobe
.
Jesper Söderqvist, CEO, Boule Diagnostics
00:00:00
Watch Full Video
×
Please Login to watch Full video
Login
+ ADD TO Wishlist
×
Please login
Login
Share On Facebook
Share On Twitter
Boule´s CEO, Jesper Söderqvist, present the interim report
Recent Videos
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio
00:10:00
Jim Woody on Leading 180 Life Sciences: Advancing Breakthrough Biologic Therapies for Inflammation, Fibrosis, and Pain|Dr. Jim Woody,CEO,180 Life Sciences
00:10:00
James Anderson: Guanajuato Silver Expands with $50M Bolanitos Deal, Building Mexico’s Fastest-Growing Silver Producer|James Anderson,CHAIRMAN & CEO,Guanajuato Silver Company Ltd
00:10:00
Highland Copper Company Targets 2026 Construction Decision as Fully Permitted Copperwood Project Gains U.S. Federal Financing Momentum|Barry O’Shea,CEO,Highland Copper
Suggestions
00:10:00
Exploring BBX Minerals' PGM Project and Bioleaching Advances with CEO Andre Duchesne
00:10:00
Invests in gender-diverse early-stage companies that are transforming business and human interaction.|Martina Welkhoff,Managing Partner,WXR Fund
00:00:00
Pharmaxis to accelerate plans for myelofibrosis combination study after FDA talks- Gary Phillips, CEO, Pharmaxis Ltd
00:00:00
MicroBix (MBX.T) CEO, Cameron L. Groome, talks antigens
00:10:00
Horizonte Minerals: Leading the Charge in Nickel Production with Tier One Projects in Brazil
00:10:00
Wealth Point Advisors: Tailored Financial Planning with Independent Expertise
00:10:00
Leveraging Active ETFs for Risk-Managed Fixed Income Strategies
00:10:00
The Importance of Exit Planning: Finding the Right Buyer at the Right Price | Brooklyn Brock, Founder, Ellevate Advisors LLC.
00:10:00
How We Analyze a Company | Henrique Bredda - Alaska Investimentos,
00:10:00
Learning Technologies Group's Jonathan Satchell and Tharisa PLC CEO discuss the company's solid Q2 performance and innovative energy storage solution.
00:10:00
Engages in a broad range of investment activities with flexibility to invest in a wide variety of asset classes|Gregg Lemkau,Chairman,MSD Capital
00:10:00
PCCW, Hong Kong's largest telco, with its president and CEO stating its achievements over 25 years, addresses limited partners and shareholders.